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for the left and right cases are statistically significant for the 
ML beam. 
   
EP-1319   
Application ACOSOG Z0011: no axillary dissection in 
women with invasive breast cancer and sentinel node 
metastasis 
I. García Ríos1, S. Sanz-Viedma2, V. Scholz3, N. Ribelles4, L. 
Vicioso5, C. Soler3, J.M. Jimenez Hoyuela2, A. Roman 
Jobacho1, J. Gomez-Millan1, E. Alba Conejo4, J.A. Medina 
Carmona1 
1Hospital Universitario Virgen de la Victoria, Radiation 
Oncology, Málaga, Spain  
2Hospital Universitario Virgen de la Victoria, Nuclear 
Medicine, Málaga, Spain  
3Hospital Universitario Virgen de la Victoria, Breast Surgeon, 
Málaga, Spain  
4Hospital Universitario Virgen de la Victoria, Medical 
Oncology, Málaga, Spain  
5Hospital Universitario Virgen de la Victoria, Pathology, 
Málaga, Spain  
 
Purpose/Objective: 
Introduction: Following the publication of the randomized 
clinical trial 'Axillary Dissection vs No Axillary Dissection in 
Women With Invasive Breast Cancer and Sentinel Node 
Metastasis' by Dr. Armando E. Giuliano et al. and taking into 
account the experience of our hospital in selective sentinel 
node dissection SLND (we performed SLND in our institution 
for 13 years to 1490 patients, 20% of the cases resulted 
metastatic sentinel node and only 8% of this cases had 
involvement of other nodes in the lymphadenectomy) , The 
Breast Cancer Committee of our hospital approved the 
implementation of the protocol ACOSOG Z0011. 
Aim: The primary end point was to determine disease free 
survival, defined as the time from diagnosis to the first 
documented recurrence of breast cancer. Breast cancer 
recurrence was categorized as locoregional disease (tumor in 
the breast or ipsilateral supraclavicular, subclavicular, 
internal mammary, or axillary nodes) or distant metastases. 
These morbidities have been reported 
Materials and Methods: Inclusion criteria: adult women with 
histologically confirmed breast carcinoma , tumor size 5 cm 
or less (T1-T2), no palpable adenopathy, negative axilla 
evaluated by ultrasound, and SLN positive for metastatic 
breast cancer documented by or hematoxylin-eosin staining 
on permanent section. Women were ineligible if they had 3 
or more positive SLNs (they received axillary lymph node 
dissection in the second time) and patients candidates to 
mastectomy. All women received whole-breast opposing 
tangential-field radiation therapy and Axillary radiotherapy 
included levels I and II. Radiation therapy not include 
supraclavicular fossa and level III. The use of adjuvant 
systemic treatment was applied at the discretion of the 
treating multidisciplinary team. 
Results: From February 2011 to June 2014, 88 patients met 
the inclusion criteria and were selected for analysis. All 
patients had invasive breast carcinoma and 1 or 2 sentinel 
node metastasis. Median follow-up was 24 months (5 – 39 
months). The average tumor size was 1.81 cm (0.6 to 3.7 
cm). Median excised lymph nodes was 2 and the median 
sentinel node with metastasis was 1. Breast cancer subtype 
was: Luminal A 42,2%, luminal B her2 – 35,6%, luminal B her2 
+ 8,9% Triple negative 8,9% , Her2 + no luminal: 4,4% 
At a median follow-up of 2 years disease-free survival was 
93.2%. 
Conclusions: In patients with limited SLN metastasis, breast 
cancer treatment with breast conservation, systemic therapy 
and radiation therapy, the use of SLND alone, avoiding the 
lymphadenectomy, provides good local control. 
Although, the results of this study are limited by the short 
follow up, we report our experience and working procedures 
to establish the ACOSOG Z0011 protocol in our center. 
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Purpose/Objective: Malignant tumors typically metastasize 
to lymph-nodes. These localizations can arise with associated 
symptoms or can be, in most cases, asymptomatic. Often 
node metastases can be the only site of active disease. It is 
reasonable to treat local metastasis with ablative therapies. 
Some evidence show that local ablative treatment can 
achieve a good response and an optimal local-disease control 
(LC). The aim of this study was to evaluate the feasibility, 
local control and the potential impact on survivals of 
stereotactic body radiotherapy in lymph-node metastases in 
oligometastatic patients. 
Materials and Methods: Fifty-eight patients with 66 lymph-
node metastases (32 male, 26 female) were treated with 
SBRT between 2009 and 2014. Site of node metastases were 
as follows: 38 (57,5%) intra-thoracic metastases, 28 (42.5%) 
abdominal/pelvic metastases. The most common primary site 
of tumor was lung 22 (38%), followed d by colon-rectum 7 
(12%) prostate 6 (10%), stomach 5 (9%), uterus 4 (7%), ovary 4 
(7%), breast 2 (3%), melanoma 2 (3%), and others (2%). Single 
fraction of 30Gy (24%) or 23Gy (26%) was used in 33 lymph 
nodes. Fractionated schedule was used for the other 33 
lymph node metastases. Variables was evaluates as 
prognostic factors. 
Results: Of the 66 pathological nodes response was achieved 
as follows: 37 nodes achieved complete response (56.2%), 
and 17 nodes achieved partial response (25.6%), while 10 
lesions had stable disease (15.2%). The progressive disease 
was observed for only 2 lesions (3%) after SBRT. The observed 
local control was 93% at 2-years. Disease-free survival was 
42.5% at 1-year and 30% at 2-years. The 1-year and 2-years 
overall survival was 80% and 65.8%, respectively. The PTV 
volume (<20 cc) was significantly associated with better DFS 
(p=0.043) and OS (p=0.001), respectively. For the other 
variables no impact on survivals was calculated. 
Conclusions: Stereotactic body therapy is feasible and safe 
for the treatment of metastatic lymph-nodes inside the 
thorax or the abdominal-pelvic area. Also, this treatment is 
efficient in a selected population of patients presenting 
oligometastic disease. SBRT can be administered even in 
patients receiving systemic therapies without increasing 
toxicity rates. 
   
 
